You can’t outsource judgment, but you don’t have to do it alone. If you’re navigating go-to-market decisions in a regulated space, work with Bill through MESH as your fractional CMO.

Talk with Bill at MESH. https://meshagency.com/about-bill-schick/ 

About this episode: Early-stage medtech founders often treat regulatory strategy as a checklist item. That mistake can cost years, capital, and credibility. In this episode, I sit down with Thomas Moore, founder of PTL Solutions, to understand why regulatory strategy is actually a business roadmap and how founders can engage with it intelligently without outsourcing their judgment.

Follow Thomas: https://www.linkedin.com/in/thomas-moore-phd-40016753/
PTL Solutions: ptl-solutions.com

00:00 Defining Regulatory Strategy 
01:13 Thomas Moore Background 
02:23 Why Regulatory Strategy Is a Core Business Tool
05:41 The Problem With Checkbox Regulatory Thinking
08:49 When Regulatory Consultants Miss the Mark
10:58 Why Founders Must Stay Engaged in Regulatory Strategy
12:26 What Investors Look for in Regulatory Planning
14:25 Can Founders Build Their Own Regulatory Strategy
16:14 Where MedTech Teams Get Stuck
21:18 The Must Have Elements of a Strong Regulatory Strategy
25:56 Why Regulatory Strategy Is Not a Linear Process

Regulatory strategy is often framed as a compliance hurdle — something to outsource, check off, and move past. But as Thomas Moore, PhD explains, that mindset quietly introduces risk across the entire business.

With over two decades in medical device development, Thomas has seen what happens when founders receive a beautifully written regulatory document they can’t defend, explain, or adapt. In this conversation, he reframes regulatory strategy as a living roadmap — one that connects product design, clinical evidence, quality systems, investor confidence, and FDA credibility.

This episode is especially relevant for early-stage medtech founders navigating limited budgets, compressed timelines, and high stakes. Thomas shares why founders don’t need to do everything themselves — but why they can’t afford to be hands-off either. From pre-subs to predicate strategy to “spinning plates” across functions, this conversation gives founders language, structure, and confidence to engage regulators and consultants from a position of clarity.

If you’re building a regulated product and trying to move fast without stepping on landmines, this episode will help you think more clearly about where regulatory fits — and why it’s inseparable from business strategy.

🎧 Subscribe to LifeSci Continuum for founder-level conversations on commercialization, regulation, and building durable life-science companies. https://meshagency.com/about-bill-schick/

#MedTechFounders #RegulatoryStrategy #LifeSciences